Cargando…
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
FMS-like tyrosine kinase 3 (FLT3) is among the most common driver genes recurrently mutated in acute myeloid leukemia (AML), accounting for approximately 30% of cases. Activating mutations of the FLT3 receptor include internal tandem duplications (ITD) that map to the auto-inhibitory juxtamembrane (...
Autores principales: | Bruno, Samantha, Bandini, Lorenza, Patuelli, Agnese, Robustelli, Valentina, Venturi, Claudia, Mancini, Manuela, Forte, Dorian, De Santis, Sara, Monaldi, Cecilia, Grassi, Alessandra, Chiurumbolo, Gabriella, Paolini, Stefania, Cristiano, Gianluca, Papayannidis, Cristina, Sartor, Chiara, Nanni, Jacopo, Ottaviani, Emanuela, Curti, Antonio, Cavo, Michele, Soverini, Simona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514815/ https://www.ncbi.nlm.nih.gov/pubmed/34660293 http://dx.doi.org/10.3389/fonc.2021.728613 |
Ejemplares similares
-
PB1865: NPM1-MUT MONITORING DURING GILTERITINIB TREATMENT IDENTIFIES DIFFERENT DYNAMICAL PATTERNS IN RESPONSIVE PATIENTS
por: Sartor, Chiara, et al.
Publicado: (2023) -
Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
por: Mancini, Manuela, et al.
Publicado: (2022) -
P558: ABSOLUTE LYMPHOCYTE COUNT IS AN INDEPENDENT SURVIVAL PREDICTOR COMPARED TO MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY
por: Cristiano, Gianluca, et al.
Publicado: (2023) -
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents
por: Papayannidis, Cristina, et al.
Publicado: (2022) -
P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS
por: Mancini, M., et al.
Publicado: (2022)